PolyCore Therapeutics
Philadelphia, US · Founded 2022 · Delaware corporation
Founders & leadership
KB
Kelly BeckMs. Beck is the Chief Executive Officer of the Issuer.
CC
Christopher CashmanNamed on SEC filing
FC
Frederick CalloriNamed on SEC filing
JB
James B. HarrisNamed on SEC filing
Board
CG
Chris GarabedianBoard director
Reported raises · per SEC filings
Form D private placements$4.7M disclosed across 1 round · 2022
▶$4.7MraisedMar 2022 · 5 investors · BiotechnologyRule 506(b)
▶$4.7MraisedMar 2022 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher CashmanDirector
- Kelly BeckExecutive Officer, Promoter, Director
- Frederick CalloriDirector
- Chris GarabedianDirector
- James B. HarrisDirector
- Offering amount
- $4.7M
- Amount sold
- $4.7M
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has PolyCore Therapeutics raised?
- PolyCore Therapeutics has disclosed $4.7M raised across 1 round.
- Where is PolyCore Therapeutics headquartered?
- PolyCore Therapeutics is headquartered in Philadelphia, US.